Who
Sabrina Martucci Johnson
Director
Company insider
Files Form 4 as: Director, AtaiBeckley; Chef Executive Officer, Dare Bioscience; Director, ATAI Life Sciences; Director, Aethlon Medical; Exec VP, CBO & CFO, Cypress Bioscience.
In numbers
- Trades disclosed
- 148
- Buys
- 0
- Sells
- 13
- Bought
- $0
- Sold
- $1.4M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 2 Jan 2006
- Last trade
- 11 Sep 2026
- Last filed
- 11 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —64,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —64,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —64,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —64,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —121,968 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —103,000 | filing |
| 11 Sep 2026filed 11 Sep 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code D | —121,968 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —121,968 at $0.00 | filing |
| 4 Jun 2026filed 8 Jun 2026 | AtaiBeckleyoption or derivative · Biotechnology | SEC FORM 4 Code A | —121,968 at $0.00 | filing |
| 18 Feb 2026filed 20 Feb 2026 | DARE Dare Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,800 | filing |
| 18 Feb 2026filed 20 Feb 2026 | DARE Dare Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,600 | filing |
| 18 Feb 2026filed 20 Feb 2026 | DARE Dare Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,800 | filing |
| 18 Feb 2026filed 20 Feb 2026 | DARE Dare Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,600 | filing |
| 30 Jan 2026filed 2 Feb 2026 | DARE Dare Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —172,000 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | DARE Dare Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —172,000 at $0.00 | filing |
| 26 Jun 2025filed 27 Jun 2025 | ATAI Life Sciencesoption or derivative | SEC FORM 4 Code A | —103,000 at $0.00 | filing |
| 28 Jan 2025filed 31 Jan 2025 | DARE Dare Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —107,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.